Pituitary gonadotropin-secreting tumors (such as GnRH-secreting adenomas) and hypothalamic hamartomas account for 60% of organic etiologies of central precocious puberty (CPP). With the advancement of high-precision imaging technology, the MRI detection rate of related lesions has increased to 15% (Chinese Journal of Pediatrics, 2025). Intracranial pituitary lesions exhibit a higher pathogenic proportion in boys with precocious puberty, reaching 30%, compared with 15% in girls.

1. Core Concept and Epidemiological Characteristics of Childhood Precocious Puberty

1.1 Medical Definition and Classification

Childhood precocious puberty is defined as the development of secondary sexual characteristics in girls before 8 years of age and in boys before 9 years of age. It is clinically categorized into three types: central precocious puberty (CPP, 80%), peripheral precocious puberty (PPP, 15%), and incomplete precocious puberty (5%). According to the China Children’s Growth and Development Health White Paper (2024), the overall incidence of precocious puberty in China is 0.43%. Among CPP cases, 2%–5% are caused by organic lesions such as pituitary tumors, representing a 1.8-fold increase compared with data from 2000, which is closely associated with rising childhood obesity rates and environmental endocrine-disrupting chemical exposure.

1.2 Pathogenic Proportion of Pituitary Tumors in Precocious Puberty

Pituitary gonadotropinomas and hypothalamic hamartomas constitute 60% of all organic causes of central precocious puberty, with a current MRI detection rate of 15% (2025). Boys with precocious puberty have a significantly higher incidence of pituitary lesions (30%) than girls (15%), and are more likely to present with accelerated linear growth (annual height increase > 10 cm) and advanced bone age (more than 2 years ahead of chronological age).

2. Pathological Mechanism: Activation of the Hypothalamic-Pituitary-Gonadal Axis

2.1 Core Triggering Mechanism of Central Precocious Puberty

Physiologically, puberty onset is triggered by pulsatile gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus. Pituitary tumors disrupt the prepubertal inhibitory mechanism through two major pathways:

Autonomous GnRH hypersecretion: Abnormal electrical discharge of hamartoma cells increases GnRH pulse frequency to over 5 times per hour (prepubertal normal < 2 times), stimulating excessive pituitary secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Approximately 20% of patients present with LH peak > 15 IU/L (prepubertal normal < 5 IU/L).

Negative feedback dysregulation: Prolactin-secreting pituitary tumors cause hyperprolactinemia (PRL > 25 ng/mL), disrupting the negative feedback loop of the gonadal axis. Up to 35% of affected children develop premature breast development and advanced menarche.

2.2 Non-Pituitary Factors in Peripheral Precocious Puberty

Adrenocortical adenomas account for 30% of peripheral precocious puberty cases, secreting excessive androgens independent of pituitary regulation. Affected girls present with premature pubic hair growth and clitoral enlargement, while boys develop penile enlargement and premature beard growth, with serum testosterone exceeding 2.5 nmol/L (normal prepubertal level < 0.7 nmol/L). Pituitary MRI shows no abnormal lesions in PPP patients.

3. Clinical Manifestations: Abnormal Secondary Sexual Characteristics and Growth Development

3.1 Age-Specific Typical Symptoms

3.1.1 Precocious Puberty in Girls (High Incidence: 7–8 Years Old)

Breast development: Areolar pigmentation and palpable breast nodules (> 1 cm in diameter); 85% of cases start unilaterally, and 12% present with pathological nipple discharge secondary to prolactinomas.

Advanced menarche: The average age of first menstruation advances to 9.5 years (normal range: 12–14 years). 20% of patients experience irregular vaginal bleeding, which requires differentiation from genital malformations.

3.1.2 Precocious Puberty in Boys (High Incidence: 6–7 Years Old)

Testicular enlargement: Testicular volume > 4 mL (normal prepubertal < 3 mL), accompanied by deepened scrotal folds and pigmentation in 60% of patients.

Premature hair and vocal changes: 50% of children develop acne and deepened voice; 15% complain of recurrent headaches (≥ 3 times weekly) caused by sellar compression from pituitary tumors.

3.3 Short-Term and Long-Term Developmental Impacts

Short-term growth acceleration: Advanced bone age leads to rapid height growth with an annual growth rate > 8 cm (normal: 5–7 cm). However, premature epiphyseal closure causes a final adult height loss of 10–15 cm (Ruijin Hospital, 2024).

Psychological impairment: 60% of affected children develop clinical anxiety (HADS score ≥ 8). Girls with early menarche have a 2.3-fold higher risk of depression, requiring early psychological intervention.

4. Diagnostic System: Three-Tier Protocol from Clinical Screening to Precise Localization

4.1 Basic Clinical Screening

Physical examination: Girls are assessed for Tanner stage ≥ 2 breast development and premature pubic hair. Boys undergo testicular volume measurement via Prader orchidometry; volume > 4 mL confirms gonadal activation. Children with height growth exceeding the 97th percentile require vigilance against combined GH elevation, with 25% of pituitary tumor patients showing IGF-1 > 358 ng/mL.

4.2 Laboratory Confirmation: Hormone Detection and Stimulation Tests

Core hormonal indicators: An LH/FSH ratio > 0.6 (prepubertal normal < 0.4) and GnRH-stimulated LH peak > 12 IU/L confirm central precocious puberty. In peripheral precocious puberty, LH and FSH remain normal while testosterone (boys) or estradiol (girls > 100 pg/mL) increases significantly.

Bone age assessment (left wrist X-ray): A bone age-chronological age gap > 2 years indicates a high-risk population, with an 8% pituitary tumor detection rate (Chinese Journal of Child Health Care, 2025).

4.3 Imaging Localization

Pituitary MRI: 3.0T thin-slice scanning (1.5 mm thickness) is the gold standard. Typical imaging features include pituitary stalk deviation (60% of tumor cases), suprasellar space-occupying lesions (common in hamartomas), and enhanced abnormal nodules > 3 mm.

Gonadal ultrasound: Ovarian volume > 1–3 mL in girls and testicular volume > 4 mL in boys confirm peripheral gonadal activation, differentiating CPP from PPP in combination with pituitary MRI findings.

5. Standardized Treatment Strategies for Childhood Precocious Puberty

5.1 Central Precocious Puberty: Gonadal Axis Suppression Therapy

5.1.1 First-Line Pharmacotherapy

GnRH agonists (GnRHa), including leuprorelin (3.75 mg every 4 weeks) and triptorelin (3.75 mg every 4 weeks), suppress LH peaks below 5 IU/L. After standardized treatment, 60% of patients experience breast regression and cessation of menstruation, with bone age progression slowed to < 1 year annually (Guidelines for Pediatric Endocrine Diagnosis and Treatment, 2024). The treatment course averages 2–3 years for children with bone age advance > 2 years and predicted adult height below the target height −2SD.

5.1.2 Surgical Intervention for Organic Lesions

Surgical indications: Pituitary tumors > 1 cm in diameter, tumors complicated with headache or visual field defects (bitemporal hemianopia from optic chiasm compression), and drug-resistant hypothalamic hamartomas.

Preferred approach: Transsphenoidal microsurgery, applicable to 90% of microadenomas with a gross total resection rate of 85%. 70% of patients achieve normalized LH levels within 3 months postoperatively.

5.2 Peripheral Precocious Puberty: Primary Disease Targeted Therapy

Laparoscopic adrenalectomy is performed for adrenocortical adenomas, with serum testosterone returning to normal within 3 weeks postoperatively, and regression of premature pubic hair and accelerated growth in 60% of children. Thyroid hormone replacement corrects hyperthyroidism-induced precocious puberty, achieving symptom relief in 30% of cases.

5.3 Adjuvant Growth and Psychological Management

Combined growth hormone therapy: For children with advanced bone age but height below the 3rd percentile, combined GnRHa and GH therapy (0.1–0.15 IU/kg/d) increases final adult height by 3–5 cm, with regular blood glucose monitoring to screen for insulin resistance (5% incidence).

Psychological intervention: Monthly family therapy and cognitive behavioral therapy (CBT) reduce HADS scores by an average of 4 points within 6 months, significantly improving social adaptation in anxious children.

6. Surgical Key Points for Pituitary Tumor-Related Precocious Puberty

6.1 Perioperative Hormone Replacement Strategy

Preoperative preparation: Children with prolactinomas receive low-dose bromocriptine pretreatment (starting at 0.625 mg/d) to reduce PRL below 50 ng/mL within 2 weeks and decrease intraoperative bleeding risk. Patients with hypocortisolism (8 a.m. cortisol < 165 nmol/L) receive preoperative hydrocortisone (5 mg/m²/d) for 3 days to prevent adrenal crisis (5% incidence).

Postoperative monitoring: Daily LH, FSH, and GH testing is performed. Postoperative LH < 5 IU/L within 1 week indicates effective gonadal axis suppression. Postoperative diabetes insipidus (urine output > 4000 mL/d) is managed with desmopressin 0.1 mg twice daily, with 20% of patients requiring long-term medication.

6.2 Perioperative Complication Prevention

Cerebrospinal fluid (CSF) leakage: Postoperative 30° head elevation is maintained. Lumbar cistern drainage and surgical repair achieve a 90% success rate for confirmed CSF rhinorrhea.

Postoperative hypopituitarism: 50% of children require long-term levothyroxine replacement (1.6 μg/kg/d), with TSH maintained at 1–2 mIU/L via regular follow-up.

7. Long-Term Follow-Up and Prognosis Evaluation

7.1 Therapeutic Evaluation Indicators

Biological indicators: After 6 months of treatment, breast/testicular volume regression ≥ 50%, LH peak < 8 IU/L, and a reduced bone age/chronological age ratio by 0.5 indicate effective intervention.

Growth indicators: Sustained annual height growth of 4–6 cm before epiphyseal closure and final adult height within ±5 cm of genetic target height are defined as successful outcomes.

7.2 Recurrence Risk Stratification

Pituitary tumor recurrence: Annual postoperative pituitary MRI surveillance is mandatory. Microadenomas have a 10% 5-year recurrence rate, while macroadenomas have a 25% recurrence rate, with close monitoring of headache and visual changes.

Precocious puberty rebound: 30% of patients develop mild LH elevation within 6 months after drug discontinuation. Quarterly sex hormone monitoring is required for 2 consecutive years.

8. Etiological Prevention and Lifestyle Modification

8.1 Avoidance of Environmental Endocrine Disruptors

Reduced use of plastic tableware minimizes bisphenol A exposure. Off-season fruits and vegetables require 10-minute soaking and cleaning to eliminate pesticide residues, with fried food intake limited to ≤ 2 times weekly. A daily sleep duration of 9–12 hours is essential, as nocturnal light exposure suppresses melatonin and triples precocious puberty risk. Daily screen time is restricted to < 2 hours.

8.2 High-Risk Population Screening

Children with a family history of precocious puberty or pituitary tumors require annual bone age examination and pituitary MRI starting at 6 years old, with a 2.5-fold higher abnormal lesion rate than the general population. Obese children with BMI > 95th percentile need semi-annual LH and FSH monitoring, with a 4-fold increased precocious puberty risk (Journal of Obesity and Endocrinology, 2024).

Frequently Asked Questions about Childhood Precocious Puberty

Q1: What should be done if a child is diagnosed with precocious puberty?

First, classify the puberty type. Central precocious puberty requires pituitary MRI to exclude organic tumors, followed by GnRHa-mediated gonadal axis suppression. Peripheral precocious puberty focuses on primary disease treatment such as adrenal tumor resection. Combined growth intervention and psychological counseling effectively reduce adult height loss and emotional disorders.

Q2: Is surgical resection required for pituitary tumor-induced precocious puberty?

Treatment depends on tumor size and clinical symptoms. Asymptomatic microadenomas (< 1 cm) can be managed with regular follow-up. Surgery is indicated for tumors > 1 cm with visual compression or drug-resistant hormonal abnormalities. Transsphenoidal microsurgery achieves an 85% gross resection rate, with 70% of children obtaining relieved precocious puberty symptoms and requiring lifelong hormonal surveillance.

Q3: Is precocious puberty hereditary?

Most sporadic cases have no obvious genetic predisposition. Rare syndromic cases such as McCune-Albright syndrome (1%) are autosomal dominant with a 90% GNAS gene mutation rate. The familial prevalence of common precocious puberty is only 1.2 times higher than the general population, without significant hereditary risk.